266 related articles for article (PubMed ID: 32439700)
1. A Pan-cancer Clinical Study of Personalized Neoantigen Vaccine Monotherapy in Treating Patients with Various Types of Advanced Solid Tumors.
Fang Y; Mo F; Shou J; Wang H; Luo K; Zhang S; Han N; Li H; Ye S; Zhou Z; Chen R; Chen L; Liu L; Wang H; Pan H; Chen S
Clin Cancer Res; 2020 Sep; 26(17):4511-4520. PubMed ID: 32439700
[TBL] [Abstract][Full Text] [Related]
2. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.
Chen Z; Zhang S; Han N; Jiang J; Xu Y; Ma D; Lu L; Guo X; Qiu M; Huang Q; Wang H; Mo F; Chen S; Yang L
Front Immunol; 2021; 12():691605. PubMed ID: 34484187
[TBL] [Abstract][Full Text] [Related]
3. Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy.
Shou J; Mo F; Zhang S; Lu L; Han N; Liu L; Qiu M; Li H; Han W; Ma D; Guo X; Guo Q; Huang Q; Zhang X; Ye S; Pan H; Chen S; Fang Y
Front Immunol; 2022; 13():1000681. PubMed ID: 36248865
[TBL] [Abstract][Full Text] [Related]
4. Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion.
Cai Z; Su X; Qiu L; Li Z; Li X; Dong X; Wei F; Zhou Y; Luo L; Chen G; Chen H; Wang Y; Zeng Y; Liu X
Mol Cancer; 2021 Dec; 20(1):164. PubMed ID: 34903219
[TBL] [Abstract][Full Text] [Related]
5. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
6. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer.
Ding Z; Li Q; Zhang R; Xie L; Shu Y; Gao S; Wang P; Su X; Qin Y; Wang Y; Fang J; Zhu Z; Xia X; Wei G; Wang H; Qian H; Guo X; Gao Z; Wang Y; Wei Y; Xu Q; Xu H; Yang L
Signal Transduct Target Ther; 2021 Jan; 6(1):26. PubMed ID: 33473101
[TBL] [Abstract][Full Text] [Related]
7. Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report.
Zeng Y; Zhang W; Li Z; Zheng Y; Wang Y; Chen G; Qiu L; Ke K; Su X; Cai Z; Liu J; Liu X
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439798
[TBL] [Abstract][Full Text] [Related]
8. Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer.
Yu YJ; Shan N; Li LY; Zhu YS; Lin LM; Mao CC; Hu TT; Xue XY; Su XP; Shen X; Cai ZZ
Cancer Immunol Immunother; 2023 Jul; 72(7):2045-2056. PubMed ID: 36795124
[TBL] [Abstract][Full Text] [Related]
9. Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.
Mørk SK; Kadivar M; Bol KF; Draghi A; Westergaard MCW; Skadborg SK; Overgaard N; Sørensen AB; Rasmussen IS; Andreasen LV; Yde CW; Trolle T; Garde C; Friis-Nielsen J; Nørgaard N; Christensen D; Kringelum JV; Donia M; Hadrup SR; Svane IM
Oncoimmunology; 2022; 11(1):2023255. PubMed ID: 35036074
[TBL] [Abstract][Full Text] [Related]
10. Engineering neoantigen vaccines to improve cancer personalized immunotherapy.
Liu Z; Lv J; Dang Q; Liu L; Weng S; Wang L; Zhou Z; Kong Y; Li H; Han Y; Han X
Int J Biol Sci; 2022; 18(15):5607-5623. PubMed ID: 36263174
[TBL] [Abstract][Full Text] [Related]
11. Therapy of genomic unstable solid tumours (WHO grade 3/4)in clinical stage III/IV using individualised neoantigen tumour peptides-INP trial (individualised neoantigen tumour peptides immunotherapy): study protocol for an open-label, non-randomised, prospective, single-arm trial.
Wang L; Tang J; Chen X; Zhao J; Tang W; Liao B; Nian W
BMJ Open; 2022 Jun; 12(6):e055742. PubMed ID: 35688598
[TBL] [Abstract][Full Text] [Related]
12. Neoantigen vaccine: an emerging tumor immunotherapy.
Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
[TBL] [Abstract][Full Text] [Related]
13. Driving neoantigen-based cancer vaccines for personalized immunotherapy into clinic: A burdensome journey to promising land.
Yu G; He X; Li X; Wu Y
Biomed Pharmacother; 2022 Sep; 153():113464. PubMed ID: 36076493
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis.
Morisaki T; Morisaki T; Kubo M; Onishi H; Hirano T; Morisaki S; Eto M; Monji K; Takeuchi A; Nakagawa S; Tanaka H; Koya N; Umebayashi M; Tsujimura K; Yew PY; Yoshimura S; Kiyotani K; Nakamura Y
Anticancer Res; 2021 Aug; 41(8):4101-4115. PubMed ID: 34281881
[TBL] [Abstract][Full Text] [Related]
15. Biomaterials-assisted construction of neoantigen vaccines for personalized cancer immunotherapy.
Wu Y; Feng L
Expert Opin Drug Deliv; 2023 Mar; 20(3):323-333. PubMed ID: 36634017
[TBL] [Abstract][Full Text] [Related]
16. Effective personalized neoantigen vaccine plus anti-PD-1 in a PD-1 blockade-resistant lung cancer patient.
Gao S; Wang J; Zhu Z; Fang J; Zhao Y; Liu Z; Qin H; Wei Y; Xu H; Dan X; Yang L; Xu Q
Immunotherapy; 2023 Feb; 15(2):57-69. PubMed ID: 36651232
[TBL] [Abstract][Full Text] [Related]
17. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer.
Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M
Clin Cancer Res; 2013 Apr; 19(8):2224-31. PubMed ID: 23479678
[TBL] [Abstract][Full Text] [Related]
18. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
Aldous AR; Dong JZ
Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
[TBL] [Abstract][Full Text] [Related]
19. A proteogenomic approach to target neoantigens in solid tumors.
Verma A; Halder A; Marathe S; Purwar R; Srivastava S
Expert Rev Proteomics; 2020; 17(11-12):797-812. PubMed ID: 33491499
[TBL] [Abstract][Full Text] [Related]
20. Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth.
Aurisicchio L; Salvatori E; Lione L; Bandini S; Pallocca M; Maggio R; Fanciulli M; De Nicola F; Goeman F; Ciliberto G; Conforti A; Luberto L; Palombo F
J Exp Clin Cancer Res; 2019 Feb; 38(1):78. PubMed ID: 30764846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]